Tibotec
In today's world, Tibotec is a highly relevant topic that has captured the attention of experts and the general public. With an impact that spans multiple aspects of daily life, Tibotec has become a point of interest for those seeking to better understand the world around them. Through its influence on society, culture, economy and politics, Tibotec has positioned itself as an inevitable topic of discussion in any field. In this article we will explore different aspects related to Tibotec, analyzing its origin, evolution and repercussions in the current world.
 | |
| Industry | Pharmaceutical |
|---|---|
| Founded | 1994 |
| Founders |
|
| Defunct | 2002 |
| Fate | Acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division |
| Website | tibotec |
Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002. The company is part of Johnson & Johnson Innovation Medicine business segment.
The name of the company is derived from the tetrahydro-imidazo-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).[1]
History
In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels joined Tibotec. The company was acquired by Johnson & Johnson in April 2002,[2] and was renamed Janssen Therapeutics in June 2011.[3]
Tibotec provided funding for HIV treatment clinical trials at the Infectious Diseases Institute in Kampala, Uganda.[4][5]
Drugs
- Darunavir (TMC114, tradename Prezista), a protease inhibitor
- Etravirine (TMC125, tradename Intelence), a non-nucleoside reverse transcriptase inhibitor (NNRTI)
- Bedaquiline (TMC207/R207910, tradename Sirturo), an diarylquinoline anti-tuberculosis drug[6]
- Rilpivirine (TMC278, tradename Edurant), an NNRTI
- Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.[7]
- Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.
See also
References
- ^ Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Gelder, Jozef Van; Woestenborghs, Robert; Heykants, Jozef; Schellekens, Karel; Janssen, Marcel A. C.; Clercq, Erik De; Janssen, Paul A. J. (1990). "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives". Nature. 343 (6257): 470–474. Bibcode:1990Natur.343..470P. doi:10.1038/343470a0. PMID 1689015. S2CID 4354080.
- ^ "Johnson & Johnson to Acquire Tibotec-Virco". Johnson & Johnson. 2002-03-22. Archived from the original on 2002-06-08. Retrieved 2023-05-16.
- ^ Van Houten, Pamela (2011-06-22). "Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies". Johnson & Johnson. Archived from the original on 2023-05-17. Retrieved 2023-05-17.
- ^ Schmickle, Sharon (2008-11-13). "University of Minnesota doctors battle AIDS in Uganda". MinnPost. Archived from the original on 2010-06-23. Retrieved 2023-05-16.
- ^ "Clinical Research at the Infectious Diseases Institute" (PDF). The Global Health Network. Infectious Diseases Institute. Archived (PDF) from the original on 2023-05-17. Retrieved 2023-05-17.
- ^ Andries, K.; Verhasselt, P; Guillemont, J; Göhlmann, H. W.; Neefs, J. M.; Winkler, H; Van Gestel, J; Timmerman, P; Zhu, M; Lee, E; Williams, P; De Chaffoy, D; Huitric, E; Hoffner, S; Cambau, E; Truffot-Pernot, C; Lounis, N; Jarlier, V (2005). "A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis". Science. 307 (5707): 223–7. Bibcode:2005Sci...307..223A. doi:10.1126/science.1106753. PMID 15591164. S2CID 33219841.
- ^ Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2.